BioPharmaDispatch Executive

In this episode, we examine funding uncertainty for genomic profiling through OMICO, structural tensions within the PBS and pharmaceutical supply chain, and broader concerns about how political and financial incentives shape health policy and budget decisions. The episode concludes with an uncomfortable discussion of recent public commentary on hostility against communities.

The Brisbane-headquartered firm is working alongside South Korea’s SK Bioscience and Germany-based IDT Biologika under a contract awarded by the European Health and Digital Executive Agency acting on behalf of the Health Emergency Preparedness and Response Authority.

MSD Australia has announced it has worked alongside patient advocacy groups, healthcare professionals and non-government organisations to launch a unified Declaration for Action aimed at improving awareness, diagnosis and long-term care for those affected.

Depending on where you are in the supply chain, the Pharmaceutical Benefits Scheme is expanding, prices are increasing, it is increasingly dominated by high-value therapies, or the program has never been more difficult to transact with.

The reality is that any new spending related to implementing the review recommendations would not be submitted to this year's Budget process without offsets. Not because of any choice, but because that is the rule.

The approvals of weight loss therapies illustrate a familiar feature of New Zealand’s medicines system. Regulatory approval can precede public funding by several years, particularly for newer or high-cost treatments.

Neurizon Therapeutics (ASX:NUZ) has entered the second half of financial year 2026 in an acceleration phase, advancing its lead drug candidate while strengthening the financial and strategic foundations needed to bring it into late-stage development.

Acrux has returned to profitability for the first half of the 2026 financial year, reporting a significant improvement in performance as recently launched products delivered their first full revenue period.

Immutep (ASX:IMM) is entering an important phase of its development journey, as rising research spending and expanding clinical trials are reshaping both its financial results and its strategic outlook.'

A new Australian study suggests that a simple blood test could help doctors better identify which head and neck cancer patients are most likely to experience a relapse after treatment.

The rapid rise of GLP-1 medicines is reshaping pharmaceutical markets across Australia and New Zealand, reflected in the first-half performance of healthcare distribution company EBOS Group.

Grünenthal has taken another step in expanding the global reach of its pain-management portfolio, signing an agreement that grants Australia-based Clinect exclusive rights to commercialise the company’s Qutenza patch in the local market.